Loading
Life sciences · Journal article
Dahuder Medical Journal · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objective: In obese breast cancer patients, aromatase inhibitors may be less effective, possibly because of increased aromatase enzyme activity in peripheral adipose tissue and higher estradiol levels. The aim of this study was to evaluate the effect of body composition on prognosis in patients with early-stage breast cancer receiving aromatase inhibitors in adjuvant endocrine therapy.Methods: Our study included patients with radiologically and histopathologically confirmed early-stage breast cancer who were admitted to Dicle University Faculty of Medicine, Department of Medical Oncology, between January 2001 and March 2017. We included postmenopausal women who had body fat percentage data and received adjuvant aromatase inhibitor therapy for hormone receptor-positive breast cancer.Results: Prognostic factors’ effects on DFS were evaluated by multivariate analysis. The analysis showed that age (p=0.637), BMI (p=0.336), lymph node positivity (p=0.114), stage (p=0.216), grade (p=0.201), lymphatic invasion (p=0.819), ER positivity (p=0.608), and Her-2 positivity (p=0.941) had no effect on prognosis. In multivariable Cox regression analysis, comorbidity status (HR: 0.70, 95% CI: 0.42–0.91, p=0.03) and body fat percentage ≥45% versus <45% (HR: 3.15, 95% CI: 1.23–8.07, p=0.01) were independently associated with DFS.Conclusion: In early-stage aromatase inhibitor-treated breast cancer patients, body fat percentage was shown to be a more valuable measure than BMI and an independent prognostic factor.